Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

Figure 6

Ex vivo binding activity of anti-CD20 IgG1 rituximab variants to CD20 on B cells. Heparinized peripheral blood from donor 5 was incubated simultaneously with 3.3 μg/mL of biotinylated anti-CD20 IgG1 and serial dilutions of non-labeled competitor anti-CD20 IgG1 rituximab on ice for 30 min. The remaining biotinylated anti-CD20 IgG1 bound to CD20+ B cell was detected by streptavidin-PE using FACS analysis. Data for the binding of biotinylated fucosylated anti-CD20 are shown.

Back to article page